[{"address1": "5750 Explorer Drive", "address2": "Suite 404", "city": "Mississauga", "state": "ON", "zip": "L4W 0A9", "country": "Canada", "phone": "905 602 5840", "website": "https://www.cipherpharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. The company was founded in 2000 and is headquartered in Mississauga, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig J. Mull", "title": "Interim CEO & Chairman of the Board", "fiscalYear": 2024, "totalPay": 253351, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryan  Jacobs", "title": "President", "fiscalYear": 2024, "totalPay": 482611, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Mailling", "title": "Chief Financial Officer", "fiscalYear": 2024, "totalPay": 207997, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 10, "compensationRisk": 5, "shareHolderRightsRisk": 2, "overallRisk": 8, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.41, "open": 10.53, "dayLow": 10.31, "dayHigh": 10.53, "regularMarketPreviousClose": 10.41, "regularMarketOpen": 10.53, "regularMarketDayLow": 10.31, "regularMarketDayHigh": 10.53, "payoutRatio": 0.0, "beta": 0.513, "trailingPE": 22.391304, "forwardPE": 20.6, "volume": 950, "regularMarketVolume": 950, "averageVolume": 9337, "averageVolume10days": 15320, "averageDailyVolume10Day": 15320, "bid": 10.33, "ask": 10.34, "bidSize": 300, "askSize": 8900, "marketCap": 261556144, "fiftyTwoWeekLow": 6.63, "fiftyTwoWeekHigh": 14.6, "priceToSalesTrailing12Months": 5.4958005, "fiftyDayAverage": 9.5296, "twoHundredDayAverage": 9.4718, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 275672192, "profitMargins": 0.25517, "floatShares": 5164338, "sharesOutstanding": 25393800, "sharesShort": 11427, "sharesShortPriorMonth": 48425, "sharesShortPreviousMonthDate": 1477872000, "dateShortInterest": 1480464000, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.42384997, "heldPercentInstitutions": 0.01342, "shortRatio": 0.97, "impliedSharesOutstanding": 25539800, "bookValue": 4.31, "priceToBook": 2.3897913, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "earningsQuarterlyGrowth": 0.968, "netIncomeToCommon": 12144000, "trailingEps": 0.46, "forwardEps": 0.5, "enterpriseToRevenue": 5.792, "enterpriseToEbitda": 16.647, "52WeekChange": -0.11435944, "SandP52WeekChange": 0.15005577, "quoteType": "EQUITY", "currentPrice": 10.3, "recommendationMean": 1.75, "recommendationKey": "buy", "totalCash": 11339000, "totalCashPerShare": 0.447, "ebitda": 16560000, "totalDebt": 25455000, "quickRatio": 1.306, "currentRatio": 1.72, "totalRevenue": 47592000, "debtToEquity": 23.26, "revenuePerShare": 1.867, "returnOnAssets": 0.04907, "returnOnEquity": 0.12252, "grossProfits": 35116000, "freeCashflow": -66023752, "operatingCashflow": 21127000, "earningsGrowth": 0.833, "revenueGrowth": 1.523, "grossMargins": 0.73786, "ebitdaMargins": 0.34796003, "operatingMargins": 0.37299, "financialCurrency": "USD", "symbol": "CPHRF", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "marketState": "CLOSED", "corporateActions": [], "regularMarketTime": 1755216000, "exchange": "OQX", "messageBoardId": "finmb_8201659", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -1.0566729, "regularMarketPrice": 10.3, "shortName": "Cipher Pharmaceuticals, Inc.", "longName": "Cipher Pharmaceuticals Inc.", "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1138890600000, "regularMarketChange": -0.10999966, "regularMarketDayRange": "10.31 - 10.53", "fullExchangeName": "OTC Markets OTCQX", "averageDailyVolume3Month": 9337, "fiftyTwoWeekLowChange": 3.67, "fiftyTwoWeekLowChangePercent": 0.5535445, "fiftyTwoWeekRange": "6.63 - 14.6", "fiftyTwoWeekHighChange": -4.3, "fiftyTwoWeekHighChangePercent": -0.29452056, "fiftyTwoWeekChangePercent": -11.435944, "earningsTimestamp": 1754596800, "earningsTimestampStart": 1762459200, "earningsTimestampEnd": 1762459200, "earningsCallTimestampStart": 1746793800, "earningsCallTimestampEnd": 1746793800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 0.46, "epsForward": 0.5, "fiftyDayAverageChange": 0.77040005, "fiftyDayAverageChangePercent": 0.08084285, "twoHundredDayAverageChange": 0.82820034, "twoHundredDayAverageChangePercent": 0.08743854, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "displayName": "Cipher Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-08-16"}]